Latest Onyx Pharmaceuticals Stories
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition THOUSAND OAKS, Calif.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
BURLINGAME, Calif., Oct.
THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc.
-Dr. Cagnoni Joins Non-Profit Organization Focused on Fostering Innovation and Collaboration to Strengthen the Bay Area BioEconomy- SAN FRANCISCO, Sept.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
- Zalani joins Intarcia to drive the strategic and operational direction of Intarcia's Global Regulatory and Quality efforts with health authorities, partners and external stakeholders -
-- Nexavar is the only approved treatment for patients with RAI-refractory differentiated thyroid cancer -- Nexavar significantly extended progression-free survival
New Chief Medical Officer Brings Wealth of Experience in Innovative Therapies in Oncology SANTA MONICA, Calif., June 2, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biopharmaceutical